Fundraising Fox
Centrexion Therapeutics
Baltimore, US · Founded 2013 · 19 employees on LinkedIn · 7 known investors
Find your way into Centrexion Therapeutics
Sign up to see every warm intro you have to Centrexion Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Centrexion Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development. The company operates in the biotechnology and pharmaceutical industry.
Founders & leadership
Centrexion Therapeutics was founded in 2013 by James N. Campbell.
KL
Kerrie L. BradyExecutiveKerrie L. Brady holds an MBA, MS in Biopharmaceuticals, and BPharm, and serves as an independent board chair and director for clinical-stage biotechnology companies, providing governance and strategic oversight on clinical development, capital planning, and investor alignment.
GB
Gregg BeloffExecutive
JB
Jeffrey B. KindlerChief Executive OfficerJeffrey Kindler served as Chairman and CEO of Pfizer, where he led the company's $68 billion acquisition of Wyeth, and previously held executive roles including General Counsel at McDonald's, President of Boston Market Corp and Partner Brands, Vice President of Litigation and Legal Policy at General Electric, and Partner at Williams & Connolly. He is currently CEO of Centrexion Therapeutics, a biotherapeutics company focused on pain drug development.
CO
Charles OhChief Medical OfficerCharles Oh is a physician and executive with experience in clinical development and medical affairs across pain management, cardiology, and neurology. He has led regulatory approvals for drug and medical device products in North America and Europe, and overseen clinical evaluations and medical affairs strategies for product launches.
MW
Mike WardChief Financial Officer/Chief Operations OfficerHe has spent over 25 years in investment banking focused on life sciences, advising on more than 100 financings and M&A transactions including nearly 20 IPOs, and previously served as CFO and Chief Business Officer at other life sciences companies.
Board
SZ
Shengda ZanBoard director
AL
Arnold L. OronskyBoard director
IB
Isaac BlechBoard director
SB
Sol BarerBoard director
Investors · 7
Catalio Capital Management, LPlisted by Catalio Capital Management, LPNew York
How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us
EFung Capitallisted by EFung CapitalShenzhen
How we know: EFung Capital's portfolio page · funding news · Not right? Tell us
New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M
How we know: funding news · Not right? Tell us
Quan Capitallisted by Quan CapitalShanghai
How we know: funding news · Not right? Tell us
6 Dimensions CapitalreportedGrand Cayman
How we know: funding news · Not right? Tell us
Avoro Capital AdvisorsreportedNew York
How we know: a partner's Signal profile · Not right? Tell us
Exome Asset ManagementreportedNew York
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$178.5M disclosed across 11 rounds · 2016–2023
▶$3.3MraisedJan 2024 · 116 investors · BiotechnologyRule 506(b)
▶$3.3MraisedJan 2024 · 116 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shawn TomaselloDirector
- Michael J. WardExecutive Officer
- James N. Campbell, M.D.Executive Officer, Director
- Sol Barer, Ph.D.Director
- Colin HillDirector
- Randall M. StevensExecutive Officer
- Joseph R. SwedishDirector
- Jeffrey B. KindlerExecutive Officer, Director
- J.C. Lopez, M.D.Director
- Offering amount
- $12.9M
- Amount sold
- $3.3M
- Sales commissions
- $1.3M
- Placement agents
- Maxim Group LLC
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedNov 2023 · 2 investors · BiotechnologyRule 506(b)
▶$2.3MraisedNov 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. WardExecutive Officer
- Shawn TomaselloDirector
- Sol Barer, Ph.D.Director
- Colin HillDirector
- J.C. Lopez, M.D.Director
- Jeffrey B. KindlerExecutive Officer, Director
- Joseph R. SwedishDirector
- Randall M. StevensExecutive Officer
- James N. Campbell, M.D.Executive Officer, Director
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- Sales commissions
- $230K
- Placement agents
- FCC Ltd., Maxim Group LLC
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.3MraisedJul 2023 · 124 investors · BiotechnologyRule 506(b)
▶$10.3MraisedJul 2023 · 124 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph R. SwedishDirector
- Randall M. StevensExecutive Officer
- Sol Barer, Ph.D.Director
- Jeffrey B. KindlerExecutive Officer, Director
- Colin HillDirector
- Michael J. WardExecutive Officer
- J.C. Lopez, M.D.Director
- James N. Campbell, M.D.Executive Officer, Director
- Shawn TomaselloDirector
- Offering amount
- $30M
- Amount sold
- $10.3M
- Sales commissions
- $3M
- Placement agents
- Maxim Group LLC
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$29.1MraisedAug 2022 · 47 investors · BiotechnologyRule 506(b)
▶$29.1MraisedAug 2022 · 47 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- J. C. Lopez, M.D.Director
- Sol BarerDirector
- Michael J. WardExecutive Officer
- James N. Campbell, M.D.Executive Officer, Director
- Peter WirthDirector
- Shawn TomaselloDirector
- Randall M. StevensExecutive Officer
- Joseph R. SwedishDirector
- Jeffrey B. KindlerExecutive Officer, Director
- Colin HillDirector
- Dezhi Kang, Ph.D.Director
- Offering amount
- $29.1M
- Amount sold
- $29.1M
- Finders' fees
- $2.6M
- Placement agents
- Maxim Group LLC
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.5MraisedJan 2021 · 17 investors · BiotechnologyRule 506(b)
▶$13.5MraisedJan 2021 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel MendelsonDirector
- Sara NayeemDirector
- Joseph R. SwedishDirector
- Shawn TomaselloDirector
- Stella XuDirector
- James N. CampbellExecutive Officer, Director
- Jeffrey B. KindlerExecutive Officer, Director
- Sol BarerDirector
- Randall M. StevensExecutive Officer
- Michael J. WardExecutive Officer
- Offering amount
- $13.5M
- Amount sold
- $13.5M
- Finders' fees
- $945K
- Placement agents
- Maxim Group LLC
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$69.6MraisedJan 2018 · 67 investors · BiotechnologyRule 506(b)
▶$69.6MraisedJan 2018 · 67 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregg BeloffExecutive Officer
- Sol J. BarerDirector
- James N. CampbellExecutive Officer, Director
- Arnold OronskyDirector
- Sara NayeemDirector
- Jeffrey B. KindlerExecutive Officer, Director
- Isaac BlechDirector
- Randall M. StevensExecutive Officer
- Shawn TomaselloDirector
- Offering amount
- $69.6M
- Amount sold
- $69.6M
- Sales commissions
- $3.6M
- Placement agents
- Maxim Group LLC, Leerink Partners LLC
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$5.3MraisedMay 2017 · 40 investors · BiotechnologyRule 506(b)
▶$5.3MraisedMay 2017 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James N. CampbellExecutive Officer, Director
- Sol J. BarerDirector
- Jeffrey B. KindlerExecutive Officer, Director
- Arnold OronskyDirector
- Randall M. StevensExecutive Officer
- Amount sold
- $5.3M
- Sales commissions
- $212.4K
- Placement agents
- CIM Securities, LLC
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$16.6MraisedJan 2017 · 14 investors · BiotechnologyRule 506(b)
▶$16.6MraisedJan 2017 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kerrie L. BradyExecutive Officer
- Sol BarerDirector
- Shengda ZanDirector
- Isaac BlechDirector
- James N. CampbellExecutive Officer, Director
- Jeffrey B. KindlerExecutive Officer
- Arnold L. OronskyDirector
- Gregg BeloffExecutive Officer
- Offering amount
- $16.6M
- Amount sold
- $16.6M
- Minimum investment
- $25K
- Sales commissions
- $1.3M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Centrexion Therapeutics.
In the news
Frequently asked questions
- What does Centrexion Therapeutics do?
- Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development. The company operates in the biotechnology and pharmaceutical industry.
- Who founded Centrexion Therapeutics?
- Centrexion Therapeutics was founded by James N. Campbell in 2013.
- Who are Centrexion Therapeutics's investors?
- Centrexion Therapeutics's investors include Catalio Capital Management, LP, EFung Capital, New Enterprise Associates (NEA), Quan Capital, 6 Dimensions Capital, Avoro Capital Advisors, Exome Asset Management.
- How much funding has Centrexion Therapeutics raised?
- Centrexion Therapeutics has disclosed $178.5M raised across 11 rounds.
- Where is Centrexion Therapeutics headquartered?
- Centrexion Therapeutics is headquartered in Baltimore, US.